John Hancock Preferred Income Fund II (HPF) Reaches $21.50 Formed H&S; Acceleron Pharma Inc. (XLRN) Had 11 Bullish Analysts

December 7, 2017 - By Jacob Smith

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Acceleron Pharma had 34 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was upgraded by Citigroup to “Buy” on Thursday, March 2. Barclays Capital maintained the stock with “Overweight” rating in Monday, June 13 report. As per Tuesday, August 1, the company rating was maintained by Oppenheimer. The firm has “Outperform” rating by FBR Capital given on Friday, January 15. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. Barclays Capital maintained the shares of XLRN in report on Wednesday, September 20 with “Overweight” rating. Oppenheimer maintained it with “Buy” rating and $4000 target in Thursday, June 1 report. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Outperform” rating by Oppenheimer on Tuesday, December 13. Credit Suisse downgraded Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Thursday, September 21. Credit Suisse has “Hold” rating and $35.0 target. UBS maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, September 12 with “Buy” rating. See Acceleron Pharma Inc. (NASDAQ:XLRN) latest ratings:

14/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $35 New Target: $51 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain
12/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $57 Initiates Coverage On
06/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $40.0 Maintain
21/09/2017 Broker: Credit Suisse Rating: Hold New Target: $35.0 Downgrade
20/09/2017 Broker: Barclays Capital Rating: Overweight Old Target: $42 New Target: $50 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $44 Initiates Coverage On
12/09/2017 Broker: UBS Rating: Buy New Target: $50.0 Maintain
04/08/2017 Broker: Credit Suisse Rating: Buy New Target: $35.0000
04/08/2017 Broker: Citigroup Rating: Buy New Target: $44.0000

John Hancock Preferred Income Fund II (HPF) formed H&S with $20.64 target or 4.00% below today’s $21.50 share price. John Hancock Preferred Income Fund II (HPF) has $456.85M valuation. The stock decreased 0.28% or $0.06 during the last trading session, reaching $21.5. About 3,758 shares traded. John Hancock Preferred Income Fund II (NYSE:HPF) has risen 1.51% since December 7, 2016 and is uptrending. It has underperformed by 15.19% the S&P500.

The stock decreased 1.60% or $0.575 during the last trading session, reaching $35.275. About 16,049 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has declined 22.43% since December 7, 2016 and is downtrending. It has underperformed by 39.13% the S&P500.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.60 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Investors sentiment increased to 1.44 in 2017 Q2. Its up 0.51, from 0.93 in 2017Q1. It increased, as 16 investors sold Acceleron Pharma Inc. shares while 27 reduced holdings. 17 funds opened positions while 45 raised stakes. 33.54 million shares or 7.21% more from 31.29 million shares in 2017Q1 were reported. Price T Rowe Md holds 0.02% or 3.85 million shares in its portfolio. Mutual Of America Cap Lc invested 0.03% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Loring Wolcott And Coolidge Fiduciary Advsrs Limited Liability Partnership Ma accumulated 337 shares. Glenmede Na holds 0% or 13,186 shares. Great Point Lc holds 493,500 shares. Sphera Funds Mngmt Limited holds 0.18% or 35,000 shares. Millennium Limited Liability stated it has 543,478 shares. Bancshares Of America De invested in 0% or 78,306 shares. American Interest Gru holds 19,880 shares or 0% of its portfolio. Citadel Ltd Limited Liability Company holds 54,549 shares or 0% of its portfolio. Birchview Ltd Partnership owns 15,000 shares or 0.24% of their US portfolio. Thompson Davis Inc has invested 0.02% in Acceleron Pharma Inc. (NASDAQ:XLRN). Blackrock Inc accumulated 0.01% or 4.01M shares. State Board Of Administration Of Florida Retirement System accumulated 18,198 shares or 0% of the stock. Metropolitan Life Insur Com Ny accumulated 22,082 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>